Radiation therapy

Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

Retrieved on: 
Friday, September 29, 2023
Biotechnology, Radiology, Health, Oncology, Real, GBM, Body mass index, Effect, ASTRO, Topical medication, Survival, Skin, Meta-analysis, Radiation treatment planning, Radiation therapy, Patient, Lung, Science in newly industrialized countries, Annual general meeting, Systematic review, Neoplasm, Epigastrium, BMI, Society, Treatment, American Society for Radiation Oncology, Software, Medical imaging, Medical device, Pharmaceutical industry, Communications satellite, Glioblastoma, Dosimetry

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego.
  • Results support the feasibility of TTFields therapy delivery to the lungs regardless of BMI and highlight the importance of choosing the appropriate array size for each patient.
  • “We are committed to continuous innovation, and we look forward to sharing new insights about the use of TTFields therapy with the scientific community,” said Pritesh Shah, Novocure’s Chief Growth Officer.
  • Tumor Treating Fields (TTFields) in the Real World for Newly Diagnosed Glioblastoma: A Survival Meta-analysis With Systematic Review.

Sun Nuclear® Solutions Supporting Better Patient Care in Focus at ASTRO 2023

Retrieved on: 
Friday, September 29, 2023
Digital, SRS, CT, Society, SSO, Drink, Anatomy, ASTRO, Quality management, Radiation therapy, QA, Annual general meeting, PET/CT, MIR, Yellow Sun (nuclear weapon), NYSE, Medical imaging

Complete Quality Management in One PlatformAvailable for demonstrations in the Sun Nuclear booth, SunCHECK software helps Radiation Oncology teams manage Patient and Machine QA in a single platform, reducing the need for disparate applications and databases. With SunCHECK software, users also gain unique workflow automation capabilities -- including automated in-vivo monitoring of real dosimetric data to catch and correct for anatomy changes throughout the treatment course. Recently released, SunCHECK version 4.2.1 offers highly anticipated enhancements, including single sign-on (SSO) for easier IT management, multiple CT-to-ED table support for improved dose calculation accuracy, improved custom template sharing and report functionality, and 100+ additional updates.

Key Points: 
  • The Sun Nuclear booth (#1835) will highlight new features and insights for the SunCHECK® Platform, new MR capabilities for proven SRS/SBRT QA solutions, and the new SIM+™ Pro laser system for patient alignment.
  • Available for demonstrations in the Sun Nuclear booth, SunCHECK software helps Radiation Oncology teams manage Patient and Machine QA in a single platform, reducing the need for disparate applications and databases.
  • Also new at ASTRO, the SIM+ Pro laser system offers best-in-class accuracy for PET/CT patient positioning, and introduces remote adjustment capabilities.
  • "In high-demand clinical settings, Radiation Oncology teams need solutions that support lean operations and deliver quantifiable efficiency gains.

Fuse Oncology Unveils FuseDocs: Newest RadOnc Solution for Streamlining Clinical Documentation for Radiation Oncologists

Retrieved on: 
Friday, September 29, 2023
Proton, Radiation, EMR, ASTRO, Fuse, PC, Radiation therapy, FuseDocs (programming), Documentation, OIS, Medical director, MD, Proton therapy, Artificial intelligence, Oncology, Health, Medical imaging, Medical device

BOONE, N.C., Sept. 29, 2023 /PRNewswire/ -- Fuse Oncology (Fuse) a trailblazing leader in radiation oncology software solutions, unveils their latest pioneering product, FuseDocs, today. This groundbreaking software leverages generative artificial intelligence (AI) to transform radiation oncology documentation, allowing oncologists to refocus their energies on patient care.

Key Points: 
  • BOONE, N.C., Sept. 29, 2023 /PRNewswire/ -- Fuse Oncology (Fuse) a trailblazing leader in radiation oncology software solutions, unveils their latest pioneering product, FuseDocs, today.
  • This groundbreaking software leverages generative artificial intelligence (AI) to transform radiation oncology documentation, allowing oncologists to refocus their energies on patient care.
  • FuseDocs leverages generative AI to transform RadOnc documentation allowing oncologists to refocus on patient care.
  • FuseDocs automatically and effortlessly generates clinical documentation, drastically reducing the time needed to produce essential records.

Naveris Announces New Data Featuring NavDx® in Oral Highlight and Poster Presentations at Upcoming ASTRO and AAO-HNSF 2023 Meetings

Retrieved on: 
Thursday, September 28, 2023
Biotechnology, Other Health, Health, General Health, Oncology, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, TTMV, Abstract, DNA, Session, San Diego Convention Center, Head, ASTRO, OPSCC, Booth, Cancer, American Academy of Otolaryngology–Head and Neck Surgery, American Academy, Radiation therapy, American Society for Radiation Oncology, MRD, MD, Annual general meeting, HPV, AM, Neoplasm, Recurrence, Society, Neck, Vaccine, Raoul de Navery

Naveris will be exhibiting at both meetings, providing the latest information on NavDx®, Naveris’ proprietary flagship blood test for tumor tissue modified viral (TTMV®)-HPV DNA.

Key Points: 
  • Naveris will be exhibiting at both meetings, providing the latest information on NavDx®, Naveris’ proprietary flagship blood test for tumor tissue modified viral (TTMV®)-HPV DNA.
  • The company will also highlight its TTMV-DNA platform in abstracts selected for oral presentation at both meetings.
  • “There is growing enthusiasm for the use of NavDx in daily practice across the continuum of HPV-driven OPSCC care, especially in the surveillance setting,” said Barry M. Berger, MD, Chief Medical Officer of Naveris.
  • Naveris and NavDx will be on exhibit at AAO-HNSF 2023 at Booth #608 and at ASTRO 2023 at Booth #3325.

TAE Life Sciences Celebrates Collaboration Milestones and Unveils Alphabeam for in-hospital BNCT at ASTRO 2023 Annual Meeting

Retrieved on: 
Thursday, September 28, 2023
Neutron, BTS, Augmented reality, ASTRO, Cancer, Hope, RaySearch Laboratories, Research, Radiation therapy, Neutron capture therapy of cancer, MD, Patient, BNCT, SAN, BPA, ABC, American Society for Radiation Oncology, Spacecraft, Society, AR, Technical, Pharmaceutical industry, Fine chemical

"We're on the verge of redefining how the world treats cancer and ASTRO is the perfect venue to showcase the capabilities of our Alphabeam BNCT system.

Key Points: 
  • "We're on the verge of redefining how the world treats cancer and ASTRO is the perfect venue to showcase the capabilities of our Alphabeam BNCT system.
  • TAE Life Sciences will host a presentation, titled "Reimagining BNCT for Biologically Targeted Radiation Therapy," at its booth stage on October 1 at 11:00 AM.
  • At ASTRO, TAE Life Sciences will have several exciting exhibits on display in its booth, including:
    BNCT treatment planning demonstration featuring TAE Life Sciences' proprietary dose engine running on the Raysearch treatment planning engine.
  • For more information about TAE Life Sciences, Alphabeam, and the company's proprietary boronated BNCT drugs, please visit www.taelifesciences.com .

Together with Siemens Healthineers, Varian Demonstrates Commitment to Embracing Innovation and Enhancing Outcomes at ASTRO 2023

Retrieved on: 
Thursday, September 28, 2023
Ethos, Eclipse, Graphics processing unit, Communication, ECLIPSE, CBCT, KG, Annual, NUALS Arts and Literary Annual Meet, Cancer, Quality of life, EDGE, Radiation therapy, Medical examiner, Sale, ARIA, Siemens Healthineers, Radiation, Acquisition, Patient, Automation, Standard of care, User, FDA, RT, American Society for Radiation Oncology, Society, Medical imaging, Nursing, Medical device, ASTRO, Varian

PALO ALTO, Calif., Sept. 28, 2023 /PRNewswire/ -- Varian, a Siemens Healthineers company, is showcasing technologies that reflect its continued commitment to embracing innovation and enhancing outcomes for cancer patients at this year's 2023 American Society for Radiation Oncology (ASTRO) annual meeting, taking place from October 1-4 in San Diego, California.

Key Points: 
  • The solutions Varian will be highlighting at ASTRO support the company's commitment to embracing innovation and enhancing outcomes by:
    By joining forces with Siemens Healthineers, a global leader in imaging, Varian is working to expand its imaging capabilities to provide solutions with improved accuracy and quality.
  • Varian is pioneering integrated software solutions to reduce redundancies and streamline workflows to unify patient care pathways and ultimately improve outcomes.
  • VARIAN, ARIA, ECLIPSE, ETHOS, HYPERSIGHT, EDGE, and TRUEBEAM are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat.
  • Siemens Healthineers is a trademark of Siemens Trademark GmbH & Co. KG registered U.S. Pat.

Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023

Retrieved on: 
Thursday, September 28, 2023
Oncology, Medical Supplies, Health, Medical Devices, Hospitals, Clinical Trials, Biotechnology, Abstract, San Diego Convention Center, Genomics, ASTRO, Research, Radiation therapy, Patient, GRID, American Society for Radiation Oncology, Biology, Urology, Society, Prostate cancer, Medical imaging

Veracyte, Inc .

Key Points: 
  • Veracyte, Inc .
  • (Nasdaq: VCYT) announced that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego.
  • The accepted abstracts include data from a large, randomized, phase 3 study that evaluated the ability of Veracyte’s Decipher Prostate test to help inform treatment decisions among patients with high-risk prostate cancer, as well as a study that assessed risk-score correlation between the gene signatures of three commercially available genomic classifiers, including the Decipher Prostate test.
  • “Data that will be shared at this year’s ASTRO meeting will demonstrate the Decipher Prostate test’s ability to help clinicians make more informed treatment decisions based on the underlying biology of the individual patient’s prostate cancer and will reinforce that prostate cancer molecular tests are not all created equal nor are they interchangeable,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.

RefleXion Showcases Breakthrough SCINTIX Biology-Guided Radiotherapy and Highlights New Research at ASTRO 2023 Meeting

Retrieved on: 
Thursday, September 28, 2023
Oncology, Health, Medical Devices, Radiology, Clinical Trials, Research, Science, Medicine, Workflow, Lung, PSMA, ASTRO, PET, Multimedia, FAP, Radiation therapy, Reflection, Patient, American Society for Radiation Oncology, FDA, Shirvani, Society, KVCT, FDG, Pharmaceutical industry, Medical imaging

RefleXion® Medical , a therapeutic oncology company, today announced the company will showcase the RefleXion® X1 with SCINTIX™ biology-guided radiotherapy at the American Society for Radiation Oncology ( ASTRO ) Annual Meeting, Oct. 1-4, 2023 in San Diego (booth #2831).

Key Points: 
  • RefleXion® Medical , a therapeutic oncology company, today announced the company will showcase the RefleXion® X1 with SCINTIX™ biology-guided radiotherapy at the American Society for Radiation Oncology ( ASTRO ) Annual Meeting, Oct. 1-4, 2023 in San Diego (booth #2831).
  • “Highlights from these presentations explore critical aspects of X1 performance in dosimetric accuracy, workflow, FDG uptake, and exquisite kVCT image quality.
  • The following oral and panel presentations highlight some of the new research being presented at ASTRO 2023.
  • The RefleXion booth will also feature a multi-target SCINTIX technology interactive demonstration and SCINTIX treatment planning demonstrations.

Sensus Healthcare Sells Superficial Radiotherapy System to Cape Cod Hospital

Retrieved on: 
Thursday, September 28, 2023
San Diego Convention Center, Community hospital, Cape Cod Hospital, Skin, ASTRO, Skin cancer, Cancer, BOCA, SRT, Booth, Radiation therapy, Sale, Pain, Sensus divinitatis, Hospital, Patient, Risk, American Society for Radiation Oncology, Society, Medical imaging

BOCA RATON, Fla. , Sept. 28, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the shipment of an SRT-100+™ System to Cape Cod Hospital in Hyannis, Massachusetts, the second SRT-100+ System sold to a hospital in Massachusetts.

Key Points: 
  • BOCA RATON, Fla. , Sept. 28, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the shipment of an SRT-100+™ System to Cape Cod Hospital in Hyannis, Massachusetts, the second SRT-100+ System sold to a hospital in Massachusetts.
  • This sale represents the Company’s ongoing success in the U.S. Northeast region as treating skin cancer with Sensus SRT technology continues to draw interest from community hospital oncology departments.
  • Jeffrey Martin, M.D., a radiation oncologist at Cape Cod Hospital, said, “Non-melanoma skin cancers affect many patients we serve.
  • To schedule an appointment or for more information about Sensus Healthcare's participation, please contact Sensus Healthcare by visiting www.sensushealthcare.com.

Sun Nuclear SunSCAN™ 3D Water Scanning System Receives CE Marking

Retrieved on: 
Thursday, September 28, 2023
Digital, CE, Prevalence, Regulation, ASTRO, 3D, Sun, Orientation, Radiation therapy, Sale, QA, Annual general meeting, MIR, Quality assurance, Yellow Sun (nuclear weapon), Society, NYSE, American Society for Radiation Oncology, Medical imaging

MELBOURNE, Fla., Sept. 28, 2023 /PRNewswire/ -- Sun Nuclear, a Mirion Medical company (NYSE: MIR), today announced achievement of the CE mark per EU Medical Device Regulation for the SunSCAN™ 3D cylindrical water scanning system. The SunSCAN 3D system supports linear accelerator (linac) commissioning, beam scanning and annual Quality Assurance (QA) in Radiation Therapy. Since its release in May 2022, the SunSCAN 3D system has found widespread clinical adoption in countries outside of those requiring the CE mark for its efficiency and hyper-accuracy. Through a rigorous regulatory review and approval process, the SunSCAN 3D system is now available for sale in countries that require CE marking.

Key Points: 
  • MELBOURNE, Fla., Sept. 28, 2023 /PRNewswire/ -- Sun Nuclear , a Mirion Medical company (NYSE: MIR), today announced achievement of the CE mark per EU Medical Device Regulation for the SunSCAN™ 3D cylindrical water scanning system .
  • The SunSCAN 3D system supports linear accelerator (linac) commissioning, beam scanning and annual Quality Assurance (QA) in Radiation Therapy.
  • Through a rigorous regulatory review and approval process, the SunSCAN 3D system is now available for sale in countries that require CE marking.
  • Building on the Sun Nuclear pioneering cylindrical water tank, the SunSCAN 3D system offers faster, easier workflows.